Exhibit (e)(10)
Y-MABS THERAPEUTICS, INC.
EXECUTIVE SEVERANCE PLAN
AND
SUMMARY PLAN DESCRIPTION
APPROVED BY
THE BOARD OF DIRECTORS: January 6, 2025
1. Introduction. The purpose of this Y-mAbs Therapeutics, Inc. Executive Severance Plan (the “Plan”) is to provide assurances of specified severance benefits to eligible executives of the Company whose employment is terminated by the Company or a successor under certain circumstances. This Plan is an “employee welfare benefit plan,” as defined in Section 3(1) of ERISA (as defined below). With the exception of certain definitions set forth below, this Plan shall supersede any individual agreement between the Company and any Covered Employee (as defined below) and any other plan, policy or practice, whether written or unwritten, maintained by the Company with respect to a Covered Employee, in each case to the extent that such agreement, plan, policy or practice provides for equity acceleration or severance benefits upon the Covered Employee’s separation from the Company. This document constitutes both the written instrument under which the Plan is maintained and the required summary plan description for the Plan.
2. Definitions. For purposes of the Plan, the terms below are defined as follows:
2.1. “Administrator” means the Board or Compensation Committee prior to a Change in Control; or, after a Change in Control, one or more members of the successor Board or Compensation Committee or other persons designated by the Company’s Board or Compensation Committee prior to such Change in Control.
2.2. “Board” means the Board of Directors of the Company.
2.3. “Cause” has the meaning ascribed to such term in any written agreement between a Covered Employee and the Company or any Affiliate of the Company defining such term and, in the absence of such agreement, such term means, with respect to a Covered Employee, the occurrence of any of the following events: (i) the Covered Employee’s commission of any felony or crime involving dishonesty; (ii) the Covered Employee’s participation in any fraud against the Company; (iii) the material breach of the Covered Employee’s duties to the Company of a nature or severity that the Company determines in its sole but reasonable discretion warrants immediate termination; (iv) the Covered Employee’s persistent unsatisfactory performance of job duties after written notice from the Company and at least thirty (30) days opportunity to cure (if deemed curable in the sole but reasonable discretion of the Company); (v) the Covered Employee’s intentional damage to any property of the Company of a material nature; (vi) the Covered Employee’s misconduct, or other violation of Company policy that causes substantial or lasting harm; (vii) the Covered Employee’s material breach of any written agreement with the Company that continues uncured for thirty (30) days; and (viii) conduct by the Covered Employee which in the good faith and reasonable determination of the Company demonstrates gross unfitness to serve.
2.4. “Change in Control” has the meaning ascribed to such term in the Equity Incentive Plan.
2.5. “Change in Control Period” means the time period commencing on the effective date of a Change in Control and ending on the first anniversary of the effective date of such Change in Control.
2.6. “COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.
2.7. “Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.
2.8. “Company” means Y-mAbs Therapeutics, Inc., a Delaware corporation, and any successor.
2.9. “Compensation Committee” means the Compensation Committee of the Board.